Evidence map›Paper›PMID 37162920›Full record

ArticlebioRxiv : the preprint server for biology2023

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus.

Colleen Furey, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Mohamad-Gabriel Alameh, Steven H Y Fan and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Colleen FureyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Naiqing YeDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lisa KercherDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jennifer DeBeauchampDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jeri Carol CrumptonDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Trushar JeevanDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Christopher PattonDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
John FranksDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Mohamad-Gabriel AlamehInfectious Disease Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Steven H Y FanAcuitas Therapeutics, Vancouver, BC, CAN.
Anthony T PhanDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christopher A HunterDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Richard J WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Drew WeissmanInfectious Disease Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Scott E HensleyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
St. Jude Children's Research Hospital · USUniversity of Pennsylvania · USAcuitas Therapeutics (Canada) · CA

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
Impact of prior influenza exposures on antibody repertoires to new viral strainsR01AI108686 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2022
$3.7M
Molecular and cellular basis of Combined Adjuvant-Elicited Cellular ImmunityR01AI126899 · NIAID · UNIVERSITY OF COLORADO DENVER · PI KEDL, ROSS M · 2016 to 2020
$2.5M
NIAID NIH HHS 75N93021C00015NIAID NIH HHS 75N93021C00016NIAID NIH HHS R01 AI108686NIAID NIH HHS R01 AI126899
6 · The paper itself

Abstract

Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. We generated an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b H5 isolate. We show that the vaccine is immunogenic in mice and ferrets and prevents morbidity and mortality of ferrets following 2.3.4.4b H5N1 challenge.

Identifiers

PMID37162920
PMCPMC10168367
OpenAlexW4367556468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.